Ketorolac Tromethamine + MoxifloxacinThird Party Manufacturing in India

Ketorolac Tromethamine + Moxifloxacin works by combining a cyclooxygenase inhibitor with a broad-spectrum fourth-generation fluoroquinolone. It blocks prostaglandin synthesis to control ocular pain and inflammation, while inhibiting bacterial DNA gyrase and topoisomerase IV to eradicate susceptible microorganisms. Unlike older generation multi-drug combinations, it offers broader anti-infective coverage and enhanced corneal penetration. It is highly effective and well-tolerated for managing post-operative recovery.

Therapeutic Uses

• Postoperative Prophylaxis: Combined prevention of bacterial infection and control of inflammatory pain after cataract surgery.
• Infectious Ocular Conditions: Management of deep bacterial corneal ulcers associated with severe localized tissue pain.

Why Manufacturers Choose Ketorolac Tromethamine + Moxifloxacin

Ketorolac Tromethamine + Moxifloxacin third party manufacturing in India is a highly profitable ophthalmic segment due to strong preference from eye surgeons for this fixed-dose combination. Our partner production sites employ advanced sterile manufacturing systems that comply fully with WHO-GMP benchmarks to ensure uniform suspension and clear clarity. Relying on WHO-GMP certified plants helps secure access to major commercial distributions and hospital procurement programs. This combination simplifies post-surgical care regimens, making it a reliable volume driver for generic brands.